Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBIT Margin: 2019-2025

Historic EBIT Margin for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -1,513.47%.

  • Avidity Biosciences' EBIT Margin rose 268747.00% to -1,513.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,934.90%, marking a year-over-year increase of 27445.00%. This contributed to the annual value of -3,477.43% for FY2024, which is 101302.00% down from last year.
  • Per Avidity Biosciences' latest filing, its EBIT Margin stood at -1,513.47% for Q3 2025, which was up 65.98% from -4,448.71% recorded in Q2 2025.
  • Avidity Biosciences' 5-year EBIT Margin high stood at -882.29% for Q1 2021, and its period low was -8,360.90% during Q1 2025.
  • Moreover, its 3-year median value for EBIT Margin was -3,043.46% (2023), whereas its average is -3,526.22%.
  • Data for Avidity Biosciences' EBIT Margin shows a peak YoY increase of 268,747bps (in 2025) and a maximum YoY decrease of 618,233bps (in 2025) over the last 5 years.
  • Avidity Biosciences' EBIT Margin (Quarterly) stood at -2,081.37% in 2021, then surged by 15,920bps to -1,922.17% in 2022, then plummeted by 112,128bps to -3,043.46% in 2023, then crashed by 102,617bps to -4,069.63% in 2024, then spiked by 268,747bps to -1,513.47% in 2025.
  • Its EBIT Margin stands at -1,513.47% for Q3 2025, versus -4,448.71% for Q2 2025 and -8,360.90% for Q1 2025.